Cookies need to be enabled on your browser for this site to work properly. Please enable cookies before proceeding. More details
This site is optimized for Firefox (v1.x), Internet Explorer (v6.x), Chrome (v0.x), Safari (v3.x) and Netscape (v7.x) on Windows and Firefox (v1.x), Netscape (v7.x) and Safari (1.3) on the Macintosh.More details
JavaScript needs to be enabled on your browser for this site to work properly. Please enable JavaScript before proceeding. More details
 
Contact Us | Help  
LOGIN HERE [ REGISTER ]
Remember Me
 
Your Cart (0) CHECKOUT >>
E-mail to colleague Print-friendly page
Study: Asthma Patients Better Using Combined Maintenance and Reliever Therapy [Source: AstraZeneca ]
(3) Add all to cart
[18-Sep-2007] New data presented at the European Respiratory Society (ERS) congress demonstrate the efficacy of budesonide/formoterol maintenance and reliever therapy (Symbicort SMART®) in reducing exacerbations and improving daily asthma control in patients with uncontrolled asthma. This data, from further analyses of the COMPASS study, show that budesonide/formoterol used as both maintenance and reliever therapy is more effective in reducing exacerbations in patients with average...
Useful Links/Documents
AstraZeneca
AstraZeneca Media Room
Press Release - Not for distribution in the US or in the UK. MS DOC
      Page  1  of  1     
Price:  FREE
AstraZeneca corporate headquarters in London, UK (Source: AstraZeneca)
Exterior shots
TRT: 00:00:34 More
Price:  FREE
AstraZeneca R&D headquarters in Sodertalje, Sweden (Source: AstraZeneca)
Exterior shots
TRT: 00:00:47 More
Price:  FREE
AstraZeneca corporate logo (Source: AstraZeneca)
Static shot
TRT: 00:00:06 More